CN111499701A - Uspa2蛋白质构建体及其用途 - Google Patents

Uspa2蛋白质构建体及其用途 Download PDF

Info

Publication number
CN111499701A
CN111499701A CN202010194047.1A CN202010194047A CN111499701A CN 111499701 A CN111499701 A CN 111499701A CN 202010194047 A CN202010194047 A CN 202010194047A CN 111499701 A CN111499701 A CN 111499701A
Authority
CN
China
Prior art keywords
ala
asn
leu
asp
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010194047.1A
Other languages
English (en)
Chinese (zh)
Inventor
N.布莱斯
C.卡斯塔多
P.乔梅茨
M.德沃钦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN111499701A publication Critical patent/CN111499701A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045Moraxella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1218Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Acinetobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202010194047.1A 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途 Pending CN111499701A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US61/943,909 2014-02-24
US201461946932P 2014-03-03 2014-03-03
US201461946937P 2014-03-03 2014-03-03
US61/946,932 2014-03-03
US61/946,937 2014-03-03
CN201580010155.6A CN106061995A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580010155.6A Division CN106061995A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Publications (1)

Publication Number Publication Date
CN111499701A true CN111499701A (zh) 2020-08-07

Family

ID=52629643

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010194047.1A Pending CN111499701A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途
CN201580010155.6A Pending CN106061995A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580010155.6A Pending CN106061995A (zh) 2014-02-24 2015-02-20 Uspa2蛋白质构建体及其用途

Country Status (28)

Country Link
US (3) US10040832B2 (cg-RX-API-DMAC7.html)
EP (2) EP3498292B1 (cg-RX-API-DMAC7.html)
JP (1) JP6585085B2 (cg-RX-API-DMAC7.html)
KR (1) KR102515835B1 (cg-RX-API-DMAC7.html)
CN (2) CN111499701A (cg-RX-API-DMAC7.html)
AU (1) AU2015220369B2 (cg-RX-API-DMAC7.html)
BE (1) BE1022345A9 (cg-RX-API-DMAC7.html)
BR (1) BR112016019525B1 (cg-RX-API-DMAC7.html)
CA (1) CA2939862C (cg-RX-API-DMAC7.html)
CY (2) CY1121535T1 (cg-RX-API-DMAC7.html)
DK (2) DK3110438T3 (cg-RX-API-DMAC7.html)
EA (1) EA034352B1 (cg-RX-API-DMAC7.html)
ES (2) ES2899300T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20190412T1 (cg-RX-API-DMAC7.html)
HU (2) HUE057505T2 (cg-RX-API-DMAC7.html)
IL (1) IL246994B (cg-RX-API-DMAC7.html)
LT (2) LT3498292T (cg-RX-API-DMAC7.html)
ME (1) ME03335B (cg-RX-API-DMAC7.html)
MX (1) MX376079B (cg-RX-API-DMAC7.html)
PL (2) PL3110438T3 (cg-RX-API-DMAC7.html)
PT (2) PT3498292T (cg-RX-API-DMAC7.html)
RS (2) RS62592B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606272PA (cg-RX-API-DMAC7.html)
SI (2) SI3110438T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100728T1 (cg-RX-API-DMAC7.html)
TW (1) TW201620927A (cg-RX-API-DMAC7.html)
UY (1) UY36006A (cg-RX-API-DMAC7.html)
WO (1) WO2015125118A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
WO2020039033A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
JP2022543281A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028333A2 (en) * 1996-12-20 1998-07-02 The Board Of Regents, The University Of Texas System USPA1 AND USPA2 ANTIGENS OF $i(MORAXELLA CATARRHALIS)
CA2618554A1 (en) * 2005-08-10 2007-02-15 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2007084053A1 (en) * 2006-01-17 2007-07-26 Arne Forsgren A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)
CN101243104A (zh) * 2005-08-10 2008-08-13 阿恩·福斯格伦股份公司 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
WO2002083710A2 (en) * 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
CA2452836C (en) * 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US20140286977A1 (en) * 2011-05-11 2014-09-25 Riesbeck Healthcare Sweden Ab Protein F - A Novel Haemophilus Influenzae Adhesin with Laminin and Vitronectin binding Properties
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028333A2 (en) * 1996-12-20 1998-07-02 The Board Of Regents, The University Of Texas System USPA1 AND USPA2 ANTIGENS OF $i(MORAXELLA CATARRHALIS)
CA2618554A1 (en) * 2005-08-10 2007-02-15 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
CN101243104A (zh) * 2005-08-10 2008-08-13 阿恩·福斯格伦股份公司 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用
US20100062027A1 (en) * 2005-08-10 2010-03-11 Arne Forsgren Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2007084053A1 (en) * 2006-01-17 2007-07-26 Arne Forsgren A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)
US20090246219A1 (en) * 2006-01-17 2009-10-01 Arne Forsgren NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOHAN SVENSSON等: "Histidine tag fusion increases expression levels of active recombinant amelogenin in Escherichia coli" *
JOHAN SVENSSON等: "Histidine tag fusion increases expression levels of active recombinant amelogenin in Escherichia coli", 《PROTEIN EXPRESSION AND PURIFICATION》, vol. 48, pages 134 - 141 *
杨雪等: "一种带有组氨酸标签的抗糖尿病疫苗的构建、表达、纯化及鉴定", 《药物生物技术》, vol. 20, no. 03, pages 189 - 193 *
王学林\N\N\N,黄文娟: "卡他球菌疫苗", no. 05, pages 5 - 8 *
程晨等: "His-tag对胆固醇氧化酶基因在大肠杆菌中表达的影响", 《工业微生物》, vol. 42, no. 5, pages 29 - 34 *
阮建兵等: "多聚组氨酸融合标签在蛋白药物开发中的应用", 《生物技术通报》, no. 06, pages 49 - 53 *

Also Published As

Publication number Publication date
PL3498292T3 (pl) 2022-02-14
ES2715674T3 (es) 2019-06-05
US10745449B2 (en) 2020-08-18
CY1124979T1 (el) 2022-11-25
EA201691611A1 (ru) 2016-12-30
LT3110438T (lt) 2019-04-10
AU2015220369B2 (en) 2018-02-01
SMT201900166T1 (it) 2019-05-10
WO2015125118A1 (en) 2015-08-27
EP3110438B1 (en) 2019-01-02
HUE057505T2 (hu) 2022-05-28
BE1022345A9 (fr) 2016-11-16
LT3498292T (lt) 2021-11-25
MX2016010954A (es) 2016-11-11
SI3498292T1 (sl) 2022-01-31
JP2017507181A (ja) 2017-03-16
ME03335B (me) 2019-10-20
HRP20211926T1 (hr) 2022-03-18
HRP20190412T1 (hr) 2019-04-19
US20180354996A1 (en) 2018-12-13
US20170008932A1 (en) 2017-01-12
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
EA034352B1 (ru) 2020-01-30
MX376079B (es) 2025-03-07
IL246994A0 (en) 2016-09-29
US20200325184A1 (en) 2020-10-15
DK3110438T3 (en) 2019-03-25
PT3498292T (pt) 2021-11-18
EP3110438A1 (en) 2017-01-04
PL3110438T3 (pl) 2019-06-28
BE1022345B1 (fr) 2016-03-25
US10947280B2 (en) 2021-03-16
ES2899300T3 (es) 2022-03-10
TW201620927A (zh) 2016-06-16
US10040832B2 (en) 2018-08-07
KR102515835B1 (ko) 2023-03-31
EP3498292A1 (en) 2019-06-19
PT3110438T (pt) 2019-03-29
RS62592B1 (sr) 2021-12-31
KR20160124774A (ko) 2016-10-28
IL246994B (en) 2020-11-30
AU2015220369A1 (en) 2016-09-15
CA2939862C (en) 2022-12-06
SG11201606272PA (en) 2016-09-29
JP6585085B2 (ja) 2019-10-02
EP3498292B1 (en) 2021-10-20
RS58451B1 (sr) 2019-04-30
HUE042054T2 (hu) 2019-06-28
CN106061995A (zh) 2016-10-26
BR112016019525A2 (pt) 2017-10-24
BR112016019525B1 (pt) 2024-01-02
SMT202100728T1 (it) 2022-01-10
CA2939862A1 (en) 2015-08-27
UY36006A (es) 2015-09-30
SI3110438T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
US10947280B2 (en) UspA2 protein constructs and uses thereof
US11198707B2 (en) Fusion proteins and combination vaccines comprising Haemophilus influenzae Protein E and Pilin A
KR20230008801A (ko) Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
CN117957016A (zh) Sars-cov-2与流感联合疫苗
CN106536544B (zh) 艰难梭菌免疫原性组合物
CN116710557A (zh) 编码sars-cov-2抗原的优化核苷酸序列
WO2019170702A1 (en) Immunogenic composition comprising uspa2 epitope
CN116940372A (zh) 流感嗜血杆菌疫苗和使用方法
EP3840770A1 (en) Immunogenic proteins and compositions
JP2014506880A (ja) 抗原性gly1ポリペプチド

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200807